Organogenesis Holdings Inc. (NASDAQ: ORGO) Stock Competitors & Peer Comparison
See ORGO's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ORGO and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ORGO | $1.72 | -1.15% | 221.3M | 57.33 | $0.03 | N/A |
| TAK | $17.98 | -0.28% | 57.2B | 12.93 | $1.39 | +3.50% |
| HLN | $10.03 | -0.79% | 44.2B | 18.72 | $0.54 | +1.23% |
| TEVA | $36.05 | -1.07% | 42B | 12.30 | $2.93 | N/A |
| ZTS | $77.10 | -0.31% | 32.3B | 11.72 | $6.58 | +2.73% |
| VTRS | $16.51 | +1.04% | 19.2B | 6.55 | $2.52 | +2.92% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $23.92 | -0.79% | 11.9B | 22.56 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $12.13 | -0.41% | 10.1B | 19.87 | $0.61 | +0.68% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
ORGO vs TAK Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, TAK has a market cap of 57.2B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while TAK trades at $17.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas TAK's P/E ratio is 12.93. In terms of profitability, ORGO's ROE is -0.24%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ORGO is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check TAK's competition here
Haleon plc (NYSE: HLN)
ORGO vs HLN Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, HLN has a market cap of 44.2B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while HLN trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas HLN's P/E ratio is 18.72. In terms of profitability, ORGO's ROE is -0.24%, compared to HLN's ROE of +0.17%. Regarding short-term risk, ORGO is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
ORGO vs TEVA Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, TEVA has a market cap of 42B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while TEVA trades at $36.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas TEVA's P/E ratio is 12.30. In terms of profitability, ORGO's ROE is -0.24%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, ORGO is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check TEVA's competition here
Zoetis Inc. (NYSE: ZTS)
ORGO vs ZTS Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, ZTS has a market cap of 32.3B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while ZTS trades at $77.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas ZTS's P/E ratio is 11.72. In terms of profitability, ORGO's ROE is -0.24%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, ORGO is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
ORGO vs VTRS Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, VTRS has a market cap of 19.2B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while VTRS trades at $16.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas VTRS's P/E ratio is 6.55. In terms of profitability, ORGO's ROE is -0.24%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, ORGO is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
ORGO vs ITCI Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ORGO's ROE is -0.24%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, ORGO is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
ORGO vs ELAN Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, ELAN has a market cap of 11.9B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while ELAN trades at $23.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas ELAN's P/E ratio is 22.56. In terms of profitability, ORGO's ROE is -0.24%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, ORGO is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
ORGO vs CTLT Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ORGO's ROE is -0.24%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ORGO is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
ORGO vs RDY Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, RDY has a market cap of 10.1B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while RDY trades at $12.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas RDY's P/E ratio is 19.87. In terms of profitability, ORGO's ROE is -0.24%, compared to RDY's ROE of +0.09%. Regarding short-term risk, ORGO is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
ORGO vs ALKS Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, ALKS has a market cap of 7.9B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while ALKS trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas ALKS's P/E ratio is 49.46. In terms of profitability, ORGO's ROE is -0.24%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, ORGO is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
ORGO vs LNTH Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while LNTH trades at $100.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas LNTH's P/E ratio is 16.97. In terms of profitability, ORGO's ROE is -0.24%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ORGO is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
ORGO vs AMRX Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while AMRX trades at $17.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas AMRX's P/E ratio is 19.41. In terms of profitability, ORGO's ROE is -0.24%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, ORGO is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
ORGO vs INDV Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, INDV has a market cap of 4.4B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while INDV trades at $34.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas INDV's P/E ratio is 9.57. In terms of profitability, ORGO's ROE is -0.24%, compared to INDV's ROE of -2.16%. Regarding short-term risk, ORGO is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check INDV's competition here
Alvotech (NASDAQ: ALVOW)
ORGO vs ALVOW Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, ALVOW has a market cap of 3B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while ALVOW trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas ALVOW's P/E ratio is 47.36. In terms of profitability, ORGO's ROE is -0.24%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, ORGO is less volatile compared to ALVOW. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check ALVOW's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
ORGO vs RGC Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while RGC trades at $5.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas RGC's P/E ratio is -388.03. In terms of profitability, ORGO's ROE is -0.24%, compared to RGC's ROE of -2.32%. Regarding short-term risk, ORGO is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check RGC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
ORGO vs SUPN Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, SUPN has a market cap of 2.6B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while SUPN trades at $44.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas SUPN's P/E ratio is 14.45. In terms of profitability, ORGO's ROE is -0.24%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, ORGO is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check SUPN's competition here
Bausch Health Companies Inc. (NYSE: BHC)
ORGO vs BHC Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while BHC trades at $6.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas BHC's P/E ratio is 1.62. In terms of profitability, ORGO's ROE is -0.24%, compared to BHC's ROE of +0.89%. Regarding short-term risk, ORGO is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
ORGO vs DCPH Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ORGO's ROE is -0.24%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ORGO is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
ORGO vs AVDL Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ORGO's ROE is -0.24%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, ORGO is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check AVDL's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
ORGO vs HCM Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while HCM trades at $12.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas HCM's P/E ratio is 4.54. In terms of profitability, ORGO's ROE is -0.24%, compared to HCM's ROE of +0.01%. Regarding short-term risk, ORGO is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check HCM's competition here
Perrigo Company plc (NYSE: PRGO)
ORGO vs PRGO Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, PRGO has a market cap of 2B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while PRGO trades at $14.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas PRGO's P/E ratio is 5.86. In terms of profitability, ORGO's ROE is -0.24%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, ORGO is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check PRGO's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
ORGO vs TRLV Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, TRLV has a market cap of 2B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while TRLV trades at $11.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas TRLV's P/E ratio is -4.68. In terms of profitability, ORGO's ROE is -0.24%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, ORGO is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check TRLV's competition here
Embecta Corp. (NASDAQ: EMBCV)
ORGO vs EMBCV Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ORGO's ROE is -0.24%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, ORGO is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
ORGO vs DVAX Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ORGO's ROE is -0.24%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ORGO is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
ORGO vs ALVO Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while ALVO trades at $5.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas ALVO's P/E ratio is -15.26. In terms of profitability, ORGO's ROE is -0.24%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, ORGO is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check ALVO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
ORGO vs ANIP Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while ANIP trades at $73.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas ANIP's P/E ratio is 8.91. In terms of profitability, ORGO's ROE is -0.24%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, ORGO is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ANIP's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
ORGO vs ETON Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, ETON has a market cap of 1.7B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while ETON trades at $60.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas ETON's P/E ratio is 131.39. In terms of profitability, ORGO's ROE is -0.24%, compared to ETON's ROE of +0.40%. Regarding short-term risk, ORGO is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ETON's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
ORGO vs TARO Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas TARO's P/E ratio is 30.05. In terms of profitability, ORGO's ROE is -0.24%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ORGO is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
ORGO vs PAHC Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, PAHC has a market cap of 1.5B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while PAHC trades at $37.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas PAHC's P/E ratio is 12.88. In terms of profitability, ORGO's ROE is -0.24%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, ORGO is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check PAHC's competition here
Harrow Health, Inc. (NASDAQ: HROW)
ORGO vs HROW Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while HROW trades at $36.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas HROW's P/E ratio is -37.28. In terms of profitability, ORGO's ROE is -0.24%, compared to HROW's ROE of -1.04%. Regarding short-term risk, ORGO is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check HROW's competition here
Cronos Group Inc. (NASDAQ: CRON)
ORGO vs CRON Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while CRON trades at $3.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas CRON's P/E ratio is 32.00. In terms of profitability, ORGO's ROE is -0.24%, compared to CRON's ROE of +0.06%. Regarding short-term risk, ORGO is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check CRON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
ORGO vs PCRX Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while PCRX trades at $25.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas PCRX's P/E ratio is 9.96. In terms of profitability, ORGO's ROE is -0.24%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, ORGO is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check PCRX's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
ORGO vs AMPH Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, AMPH has a market cap of 993.4M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while AMPH trades at $22.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas AMPH's P/E ratio is 7.69. In terms of profitability, ORGO's ROE is -0.24%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, ORGO is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check AMPH's competition here
PetIQ, Inc. (NASDAQ: PETQ)
ORGO vs PETQ Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ORGO's ROE is -0.24%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ORGO is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
ORGO vs COLL Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, COLL has a market cap of 798.2M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while COLL trades at $24.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas COLL's P/E ratio is 3.09. In terms of profitability, ORGO's ROE is -0.24%, compared to COLL's ROE of +0.16%. Regarding short-term risk, ORGO is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
ORGO vs IRWD Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, IRWD has a market cap of 699.6M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while IRWD trades at $4.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas IRWD's P/E ratio is 5.45. In terms of profitability, ORGO's ROE is -0.24%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, ORGO is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check IRWD's competition here
Glass House Brands Inc (NYSE: GLAS)
ORGO vs GLAS Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, GLAS has a market cap of 691M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while GLAS trades at $8.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas GLAS's P/E ratio is -15.95. In terms of profitability, ORGO's ROE is -0.24%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, ORGO is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check GLAS's competition here
Evotec SE (NASDAQ: EVO)
ORGO vs EVO Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, EVO has a market cap of 667.9M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while EVO trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas EVO's P/E ratio is -2.65. In terms of profitability, ORGO's ROE is -0.24%, compared to EVO's ROE of -0.27%. Regarding short-term risk, ORGO is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check EVO's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
ORGO vs AQST Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, AQST has a market cap of 641.1M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while AQST trades at $5.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas AQST's P/E ratio is -7.86. In terms of profitability, ORGO's ROE is -0.24%, compared to AQST's ROE of +2.44%. Regarding short-term risk, ORGO is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check AQST's competition here
Evolus, Inc. (NASDAQ: EOLS)
ORGO vs EOLS Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, EOLS has a market cap of 598.6M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while EOLS trades at $9.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas EOLS's P/E ratio is -28.79. In terms of profitability, ORGO's ROE is -0.24%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, ORGO is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check EOLS's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
ORGO vs BDSI Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ORGO's ROE is -0.24%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ORGO is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
ORGO vs TLRY Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, TLRY has a market cap of 511.1M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while TLRY trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas TLRY's P/E ratio is -4.22. In terms of profitability, ORGO's ROE is -0.24%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, ORGO is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check TLRY's competition here
Kamada Ltd. (NASDAQ: KMDA)
ORGO vs KMDA Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, KMDA has a market cap of 474.8M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while KMDA trades at $8.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas KMDA's P/E ratio is 21.66. In terms of profitability, ORGO's ROE is -0.24%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, ORGO is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
ORGO vs CGC Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, CGC has a market cap of 420M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while CGC trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas CGC's P/E ratio is -0.60. In terms of profitability, ORGO's ROE is -0.24%, compared to CGC's ROE of -0.33%. Regarding short-term risk, ORGO is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
ORGO vs TKNO Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, TKNO has a market cap of 384.9M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while TKNO trades at $7.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas TKNO's P/E ratio is -23.16. In terms of profitability, ORGO's ROE is -0.24%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, ORGO is more volatile compared to TKNO. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check TKNO's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
ORGO vs EBS Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, EBS has a market cap of 314.2M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while EBS trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas EBS's P/E ratio is 4.23. In terms of profitability, ORGO's ROE is -0.24%, compared to EBS's ROE of -0.36%. Regarding short-term risk, ORGO is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
ORGO vs ALIM Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ORGO's ROE is -0.24%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ORGO is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
ORGO vs LNDC Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ORGO's ROE is -0.24%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, ORGO is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
ORGO vs ACB Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, ACB has a market cap of 250.9M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while ACB trades at $4.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas ACB's P/E ratio is -8.27. In terms of profitability, ORGO's ROE is -0.24%, compared to ACB's ROE of -0.21%. Regarding short-term risk, ORGO is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ACB's competition here
Shineco, Inc. (NASDAQ: TYHT)
ORGO vs TYHT Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ORGO's ROE is -0.24%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ORGO is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check TYHT's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
ORGO vs CRDL Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, CRDL has a market cap of 227.7M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while CRDL trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas CRDL's P/E ratio is -7.87. In terms of profitability, ORGO's ROE is -0.24%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, ORGO is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check CRDL's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
ORGO vs SIGA Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, SIGA has a market cap of 225.2M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while SIGA trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas SIGA's P/E ratio is 11.63. In terms of profitability, ORGO's ROE is -0.24%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, ORGO is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check SIGA's competition here
Journey Medical Corporation (NASDAQ: DERM)
ORGO vs DERM Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, DERM has a market cap of 203.9M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while DERM trades at $7.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas DERM's P/E ratio is -20.03. In terms of profitability, ORGO's ROE is -0.24%, compared to DERM's ROE of -0.20%. Regarding short-term risk, ORGO is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check DERM's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
ORGO vs REPH Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas REPH's P/E ratio is -8.04. In terms of profitability, ORGO's ROE is -0.24%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ORGO is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check REPH's competition here
Organigram Global Inc. (NASDAQ: OGI)
ORGO vs OGI Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, OGI has a market cap of 170.3M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while OGI trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas OGI's P/E ratio is 2.72. In terms of profitability, ORGO's ROE is -0.24%, compared to OGI's ROE of +0.21%. Regarding short-term risk, ORGO is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
ORGO vs LFCR Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, LFCR has a market cap of 167.3M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while LFCR trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas LFCR's P/E ratio is -4.17. In terms of profitability, ORGO's ROE is -0.24%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, ORGO is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check LFCR's competition here
Theratechnologies Inc. (NASDAQ: THTX)
ORGO vs THTX Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas THTX's P/E ratio is -28.83. In terms of profitability, ORGO's ROE is -0.24%, compared to THTX's ROE of +0.17%. Regarding short-term risk, ORGO is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
ORGO vs ASRT Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas ASRT's P/E ratio is -7.10. In terms of profitability, ORGO's ROE is -0.24%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, ORGO is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
ORGO vs SCTL Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ORGO's ROE is -0.24%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ORGO is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
ORGO vs BGM Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, BGM has a market cap of 103.5M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while BGM trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas BGM's P/E ratio is -0.94. In terms of profitability, ORGO's ROE is -0.24%, compared to BGM's ROE of -0.05%. Regarding short-term risk, ORGO is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
ORGO vs PROC Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas PROC's P/E ratio is 1.53. In terms of profitability, ORGO's ROE is -0.24%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ORGO is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check PROC's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
ORGO vs CPIX Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, CPIX has a market cap of 100.2M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while CPIX trades at $6.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas CPIX's P/E ratio is -16.73. In terms of profitability, ORGO's ROE is -0.24%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, ORGO is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check CPIX's competition here
OptiNose, Inc. (NASDAQ: OPTN)
ORGO vs OPTN Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ORGO's ROE is -0.24%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, ORGO is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
ORGO vs ZOM Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ORGO's ROE is -0.24%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, ORGO is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
ORGO vs GRVI Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ORGO's ROE is -0.24%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, ORGO is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
ORGO vs ZYBT Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, ZYBT has a market cap of 82M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while ZYBT trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas ZYBT's P/E ratio is -7.86. In terms of profitability, ORGO's ROE is -0.24%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, ORGO is more volatile compared to ZYBT. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
ORGO vs ZYNE Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ORGO's ROE is -0.24%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ORGO is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check ZYNE's competition here
InterCure Ltd. (NASDAQ: INCR)
ORGO vs INCR Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, INCR has a market cap of 68.2M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while INCR trades at $5.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas INCR's P/E ratio is -13.30. In terms of profitability, ORGO's ROE is -0.24%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ORGO is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check INCR's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
ORGO vs SSIC Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ORGO's ROE is -0.24%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ORGO is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check SSIC's competition here
Talphera, Inc. (NASDAQ: TLPH)
ORGO vs TLPH Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, TLPH has a market cap of 61.8M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while TLPH trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas TLPH's P/E ratio is -3.84. In terms of profitability, ORGO's ROE is -0.24%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, ORGO is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check TLPH's competition here
The Valens Company Inc. (NASDAQ: VLNS)
ORGO vs VLNS Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ORGO's ROE is -0.24%, compared to VLNS's ROE of N/A. Regarding short-term risk, ORGO is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
ORGO vs DRRX Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ORGO's ROE is -0.24%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, ORGO is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
ORGO vs JUPW Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ORGO's ROE is -0.24%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, ORGO is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
ORGO vs QLI Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas QLI's P/E ratio is -4.92. In terms of profitability, ORGO's ROE is -0.24%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ORGO is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check QLI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
ORGO vs CPHI Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, CPHI has a market cap of 35.9M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while CPHI trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas CPHI's P/E ratio is -2.06. In terms of profitability, ORGO's ROE is -0.24%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, ORGO is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check CPHI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
ORGO vs RMTI Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, RMTI has a market cap of 32.8M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while RMTI trades at $8.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas RMTI's P/E ratio is -6.20. In terms of profitability, ORGO's ROE is -0.24%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, ORGO is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
ORGO vs HEXO Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ORGO's ROE is -0.24%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ORGO is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check HEXO's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
ORGO vs TXMD Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, TXMD has a market cap of 25.2M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while TXMD trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas TXMD's P/E ratio is 111.05. In terms of profitability, ORGO's ROE is -0.24%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, ORGO is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
ORGO vs AYTU Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, AYTU has a market cap of 24.6M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while AYTU trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas AYTU's P/E ratio is -1.19. In terms of profitability, ORGO's ROE is -0.24%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, ORGO is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check AYTU's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
ORGO vs CYTH Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ORGO's ROE is -0.24%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ORGO is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
ORGO vs EVOK Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ORGO's ROE is -0.24%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, ORGO is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
ORGO vs OPTH Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, OPTH has a market cap of 15.9M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while OPTH trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas OPTH's P/E ratio is -18.04. In terms of profitability, ORGO's ROE is -0.24%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, ORGO is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
ORGO vs ACRX Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ORGO's ROE is -0.24%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, ORGO is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
ORGO vs CABR Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, CABR has a market cap of 12.2M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while CABR trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas CABR's P/E ratio is -2.39. In terms of profitability, ORGO's ROE is -0.24%, compared to CABR's ROE of -3.86%. Regarding short-term risk, ORGO is more volatile compared to CABR. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
ORGO vs AGRX Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ORGO's ROE is -0.24%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ORGO is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
ORGO vs NLTX Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ORGO's ROE is -0.24%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, ORGO is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
ORGO vs LCI Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas LCI's P/E ratio is -0.04. In terms of profitability, ORGO's ROE is -0.24%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ORGO is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
ORGO vs ADMP Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ORGO's ROE is -0.24%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ORGO is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
ORGO vs YCBD Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, YCBD has a market cap of 5.1M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while YCBD trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas YCBD's P/E ratio is -1.21. In terms of profitability, ORGO's ROE is -0.24%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, ORGO is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
ORGO vs GELS Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, GELS has a market cap of 5M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while GELS trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas GELS's P/E ratio is -1.10. In terms of profitability, ORGO's ROE is -0.24%, compared to GELS's ROE of -0.25%. Regarding short-term risk, ORGO is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
ORGO vs MNK Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas MNK's P/E ratio is -0.44. In terms of profitability, ORGO's ROE is -0.24%, compared to MNK's ROE of -0.36%. Regarding short-term risk, ORGO is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
ORGO vs FLGC Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ORGO's ROE is -0.24%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, ORGO is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
ORGO vs UPC Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, UPC has a market cap of 2.9M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while UPC trades at $4.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas UPC's P/E ratio is -0.57. In terms of profitability, ORGO's ROE is -0.24%, compared to UPC's ROE of -0.03%. Regarding short-term risk, ORGO is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check UPC's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
ORGO vs RDHL Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, RDHL has a market cap of 2.9M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while RDHL trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas RDHL's P/E ratio is 0.18. In terms of profitability, ORGO's ROE is -0.24%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, ORGO is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check RDHL's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
ORGO vs SBFM Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, SBFM has a market cap of 2.7M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while SBFM trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas SBFM's P/E ratio is -0.18. In terms of profitability, ORGO's ROE is -0.24%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, ORGO is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
ORGO vs PLXP Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas PLXP's P/E ratio is -0.22. In terms of profitability, ORGO's ROE is -0.24%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, ORGO is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
ORGO vs ATNX Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas ATNX's P/E ratio is -0.02. In terms of profitability, ORGO's ROE is -0.24%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, ORGO is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
ORGO vs SNOA Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while SNOA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas SNOA's P/E ratio is -1.09. In terms of profitability, ORGO's ROE is -0.24%, compared to SNOA's ROE of -0.46%. Regarding short-term risk, ORGO is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check SNOA's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
ORGO vs SHPH Comparison September 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 221.3M. In comparison, SHPH has a market cap of 2.1M. Regarding current trading prices, ORGO is priced at $1.72 on the NASDAQ, while SHPH trades at $3.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 57.33, whereas SHPH's P/E ratio is -0.17. In terms of profitability, ORGO's ROE is -0.24%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, ORGO is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check SHPH's competition here